Skip to main content

Table 1 Baseline characteristics of patients included in the study

From: Association between concomitant csDMARDs and clinical response to TNF inhibitors in overweight patients with axial spondyloarthritis

Characteristics Total patients (n = 246) Included patients (n = 180) Included patients BMI ≤ 25 (n = 78) Included patients BMI > 25 (n = 102)
Age (years) 47.6 ± 13.1 47.0 ± 12.7 42.9 ± 11.7 50.1 ± 12.6***
Male 146 (59) 107 (59) 39 (50) 68 (67)*
Disease duration (years) 10 (5–16) 8 (5–16) 7 (3–13) 9 (6–18)**
SpA subtype
 Ankylosing spondylitis 179 (78) 140 (78) 64 (82) 76 (74)
 Non-radiographic SpA 49 (22) 40 (22) 14 (18) 26 (26)
HLA-B27 174 (74) 131 (73) 61 (78) 70 (69)
Psoriasis/IBD/uveitis 71 (29) 58 (32) 27 (35) 31 (30)
Peripheral arthritis 97 (40) 86 (48) 38 (49) 48 (47)
BASDAI 5.8 ± 2.0 5.8 ± 2.0 5.5 ± 2.1 6.0 ± 1.9
ASDAS 3.3 ± 0.9 3.3 ± 1.0 3.2 ± 1.0 3.4 ± 1.0
ESR (mmHg) 17 (7–33) 17 (7–31) 19 (6–34) 16 (7–31)
CRP (mg/L) 5 (2–15) 6 (3–17) 7 (2–20) 5 (3–15)
Previous TNFi 43 (18) 35 (19) 13 (17) 22 (21)
TNFi type
 Infliximab 107 (43) 74 (41) 25 (32) 49 (48)*
 Adalimumab 139 (57) 106 (59) 53 (68) 53 (52)*
csDMARD
 Any csDMARD 102 (42) 79 (44) 31 (40) 48 (47)
 MTX 34 (15) 25 (14) 12 (15) 13 (13)
 SSZ 46 (21) 36 (20) 10 (13) 26 (25)*
 MTX and SSZ 22 (9) 18 (10) 9 (11) 9 (9)
Prednisone 22 (9) 20 (11) 11 (14) 9 (9)
  1. The table shows mean ± SD, median (IQR) or absolute number (percentage) for all patients included (n = 180). The results are also stratified by body mass index (BMI). p value < 0.05 was considered statistically significant. Significant statistical differences between the groups of included patients, stratified by BMI: *p < 0.05, **p < 0.01, ***p < 0.001. SpA spondyloarthritis, HLA-B27 human leucocyte antigen B27, ESR erythrocyte sedimentation rate, CRP C-reactive protein, IBD inflammatory bowel disease, BASDAI Bath Ankylosing Spondylitis Disease Activity Index, ASDAS Ankylosing Spondylitis Disease Activity Index, TNFi tumour necrosis factor inhibitors, csDMARD conventional synthetic disease-modifying anti-rheumatic drug, MTX methotrexate, SSZ sulfasalazine